INFLUENCE OF SLCO1B1 GENE C.T521>C POLYMORPHISM ON THERAPY WITH SIMVASTATIN IN CORONARY HEART DISEASE PATIENTS

DOI: https://doi.org/None

Kotlovskiy M.Yu., Pokrovskiy A.A., Osedko A.V., Osedko O.Ya., Kotlovskaya O.S., Yakimenko A.V., Kurdoyak E.V., Yakimovich I.Yu., Aksyutina N.V., Titova N.M., Kotlovskiy Yu.V., Dygai A.M.

Introduction. Carrier protein OATP1B1, encoded by the SLCO1B1gene, is involved in the transport of simvastatin into liver cells. SLCO1B1 gene polymorphisms influence on the functionality of the transporter, which could reflect on the efficacy and safety of treatment. Aim of the study. The study of the influence of SLCO1B1 Gene c.T521>C polymorphism on the efficacy of the treatment with simvastatin in coronary heart disease patients Materials and methods. The study group included 42 cases in whom there was assessed the level of total cholesterol, low-density lipoproteins and triglycerides before and after treatment. To identify a single nucleotide polymorphism MALDI-TOF mass spectrometer was used. Results. A statistically significant difference in the reducing of total cholesterol and achievement of cholesterol goal levels was revealed in dependence on the SLCO1B1 genotype. The efficiency of reduction of total cholesterol and the achievement of cholesterol goal levels in carriers of normal homozygote was higher than in C-alleles carriers by 61,9% and 34,8% correspondingly Conclusion. Thus, in our study there was found an association between polymorphic marker of the SLCO1B1 gene and the level of plasma lipids in the treatment of male coronary heart disease patients with simvastatin
Keywords: 
SLCO1B1, polymorphism, simvastatin
Список литературы: 
  1. Oganov R.G., Maslennikova G.Ya. Demograficheskie tendencii v Rossiyskoy Federacii: vklad bolezney sistemy krovoobrashheniya. Kardiovaskulyarnaya terapiya i profilaktika. 2012; 1: 5–10. [Oganov R.G., Maslennikova G.Ja. Demographic trends in the Russian Federation: the impact of cardiovascular disease. Cardiovascular Therapy and Prevention. 2012; 1: 5–10 (in Russian)]
  2. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Ranel III). JAMA. 2001; 285: 2486–97.
  3. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high–risk individuals: a randomised placebocontrolled trial. Lancet. 2002; 360: 7–22.
  4. Pedersen T.R., Berg K. Safety and tolerability of cholesterol lowering with simvastatin during years in the Scandinavian simvastatin survival study. Arch. Int. Med. 2000; 176: 1976–84.
  5. Kajinami K., Takekoshi N., BrousseauM.E., Schaefer E.J. Pharmacogenetics of HMG-Co A reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart diseasemanagement. Atherosclerosis. 2004; 177 (2): 219–34.
  6. Hagenbuch B., Meier P.J. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 2004; 447: 653–65.
  7. Iwai M., Suzuki H., Ieiri I., Otsubo K., Sugiyama Y. Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics. 2004; 14 (11): 749–57.
  8. Niemi M., Pasanen M.K., and Neuvonen P.J. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol. Rev. 2011; 63 (1): 157–81.
  9. Zhou Q., Chen Q.X., Ruan Z.R., Yuan H., Xu H.M., Zeng S. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics. Pharmazie. 2013; 68 (3): 187–94.
  10. Voskoboynikov A.M., Grachev A.V., Knyazeva G.P., Sychev D.A. Farmakogeneticheskoe testirovanie po allel`nomu variantu SLCO1B1*5: znachenie dlya personalizacii dozirovaniya statinov u pacientov s giperlipidemiyami. Byulleten` Medicinskih Internet-konferenciy. 2013; 3 (6): 975–6. [Voskobojnikov A.M., Grachev A.V., Knjazeva G.P., Sychev D.A. Pharmacogenetic testing for allelic variants of SLCO1B1* 5: implications for personalization dosing of statins in patients with hyperlipidemia. Bulletin of Medical Internet Conference. 2013; 3 (6): 975–6 (in Russian)]
  11. Sirotkina A.M., Hohlov A.L., Mogutova I.S., Voronina E.A., Careva I.N. Rasprostranennost` polimorfnogo markera gena SLCO1B1 u pacientov s giperlipidemiey i nekotoryh polimorfnyh variantov genov u bol`nyh s arterial`noy gipertenziey. Nauka i sovremennost`. Sbornik materialov XXIV Mezhdunarodnoy zaochnoy nauchno-prakticheskoy konferencii. 09.09.2013. Novosibirsk: NP SibAK, 2013; 90–6. [Sirotkina A.M., Hohlov A.L., Mogutova I.S., Voronina E.A., Careva I.N. Prevalence of polymorphic marker gene SLCO1B1 in patients with hyperlipidemia and some polymorphic variants of genes in patients with hypertension. Science and modernity. Collected materials XXIV International extramural scientific-practical conference. 09.09.2013. Novosibirsk: NP SibAK, 2013; 90–6 (in Russian)]
  12. Meyer zu Schwabedissen H., Albers M., Baumeister S., Rimmbach C., Nauck M., Wallaschofski H., Siegmund W., Völzke H., Kroemer H. Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort. Pharmacogenet. Genomics. 2015; 25 (1): 8–18.